Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Valeant Pharmaceuticals Intl Inc    VRX   CA91911K1021

VALEANT PHARMACEUTICALS INTL INC (VRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
34.65(c) 34.89(c) 35.07(c) 35.47(c) 31.09 Last
1 293 485 1 372 578 1 022 677 2 350 876 2 389 826 Volume
+0.70% +0.69% +0.52% +1.14% -12.35% Change
More quotes
Financials (USD)
Sales 2018 8 499 M
EBIT 2018 3 067 M
Net income 2018 -3 123 M
Debt 2018 23 708 M
Yield 2018 -
Sales 2019 8 423 M
EBIT 2019 3 053 M
Net income 2019 -1 475 M
Debt 2019 22 486 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 3,89x
EV / Sales2019 3,78x
Capitalization 9 371 M
More Financials
Company
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products.It operates through the following segments: The Bausch + Lomb/International, Branded Rx,... 
Sector
Pharmaceuticals
Calendar
08/07Earnings Release
More about the company
Surperformance© ratings of Valeant Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on VALEANT PHARMACEUTICALS IN
08:01aVALEANT PHARMACEUTICALS INTL : FDA Issues Complete Response Letter For DUOBRII&t..
PR
07:41aVALEANT PHARMACEUTICALS INTL : Bausch + Lomb Launches Soothe Xtra Protection Pre..
AQ
06/14VALEANT PHARMACEUTICALS INTL : Argentum Pharmaceuticals Wins Patent Invalidation..
AQ
06/14BAUSCH + LOMB : Launches Soothe® Xtra Protection Preservative Free Lubricant Eye..
PR
06/13VALEANT PHARMACEUTICALS INTL : Rises
AQ
06/12VALEANT PHARMACEUTICALS INTL : Announces News, Hits 52-Week High
AQ
06/12BAUSCH + LOMB : Introduces Ocuvite® Blue Light Eye Vitamins
PR
06/11VALEANT PHARMACEUTICALS INTL INC : Today's Research Reports on Trending Tickers:..
AC
06/08VALEANT PHARMACEUTICALS INTL : Securities Class Action Filed on Behalf of Person..
BU
06/06VALEANT PHARMACEUTICALS INTL : Which Biotechnology Stocks are Trending Today?
AQ
More news
Sector news : Pharmaceuticals - NEC
10:30aHow U.S. tax reform rewards companies that shift profit to tax havens
RE
05:29aEvotec Shares Jump After It Secures Sanofi Agreement
DJ
03:43aIndivior shares rise after U.S. court order blocks generic rival drug
RE
02:51aINDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
02:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
04:47pValeant shares drop 5% after FDA fails to approve plaque psoriasis lotion: Va.. 
06/14$VRX Pharmaceuticals International, Inc Valeant Pharmaceuticals Internationa.. 
06/14Valeant Pharmaceuticals Intl Inc $VRX Given Average Recommendation of “Hold” .. 
06/07Valeant Pharmaceuticals Intl $VRX Upgraded to “Overweight” at Barclays  
06/05Valeant Pharmaceuticals International $VRX Reaches New 52-Week High at $30.38.. 
More tweets
Qtime:140
News from SeekingAlpha
09:06aFDA rejects Valeant's application for psoriasis lotion Duobrii; shares down 5.. 
06/15Key events next week - healthcare 
06/12Will The Rite Aid - Albertsons Merger Fall Apart? 
06/11The 'Joe Papa' Effect Is Arriving At Valeant 
06/08MALLINCKRODT : The Cheapest Stock In Global Healthcare 
Chart VALEANT PHARMACEUTICALS IN
Duration : Period :
Valeant Pharmaceuticals In Technical Analysis Chart | VRX | CA91911K1021 | 4-Traders
Technical analysis trends VALEANT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 16,9 $
Spread / Average Target -37%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Jerzy Janeczko Head-Information Technology
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VALEANT PHARMACEUTICALS INTL INC35.38%9 371
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880